GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.
InvestorsHub on MSN
Kodiak Sciences shares jump on encouraging Phase 3 trial results
Shares of Kodiak Sciences Inc. (NASDAQ:KOD) surged about 26% on Thursday after the company reported positive topline data ...
Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
AstraZeneca (AZN) stock is in focus as respiratory drug tozorakimab meets main goals in two Phase 3 trials for chronic ...
Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...
Treatment speed and patient perception are emerging as key factors in managing pattern hair loss, especially as many patients ...
InvestorsHub on MSN
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares climbed 10% on Tuesday after the company released mixed results from its Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib for ...
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 ...
Myelofibrosis morbidity is driven by splenomegaly, systemic symptoms, and anemia; discontinuation of JAK inhibitors exceeds ...
(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical trial updates session and presentation by Dr. Michael Morris discussing DORA and PEACE-3 and the evolving role of radium-223. Dr.
Inhaled treprostinil is associated with a smaller decline in FVC and fewer clinical worsening events in patients with IPF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results